CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors

NCT04691713 | Unknown

• 1 other identifier: PG-CART-276-001
• Study Type: interventional
• Target: 5
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a clinical study of CD276 CAR-T in the treatment of patients with advanced solid tumors. The purpose is to evaluate the safety and effectiveness of targeting CD276 auto-chimeric antigen receptor T cells in the treatment of CD276-positive advanced solid tumors.

Conditions

CAR; Solid Tumor

Outcome Measures

Primary Outcomes (1)

• ORR 3

  3-month objective response rate

  Three months after CAR T cell infusion

Study Arms (1)

Targeting CD276 autologous chimeric antigen receptor T cells

EXPERIMENTAL

Drug: Targeting CD276 autologous chimeric antigen receptor T cells

Interventions

Targeting CD276 autologous chimeric antigen receptor T cells DRUG

Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner, which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.

Targeting CD276 autologous chimeric antigen receptor T cells

Eligibility Criteria

• Age: 3 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 3-70
• Expected survival time ≥ 12weeks
• ECOG 0-2
• At least second-line or above chemotherapy failed
• According to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1), at least one measurable lesion (non-nodular lesion with longest diameter ≥10mm, or nodular lesion with short diameter ≥15mm)
• Liver and kidney function, heart and lung function meet the following requirements:
• Creatinine is within the normal range;
• Left ventricular ejection fraction ≥ 45%;
• Baseline blood oxygen saturation\>91%;
• Total bilirubin≤1.5×ULN; ALT and AST≤2.5×ULN
• Understand the trial and have signed the informed consent

You may not qualify if:

• Those who have graft-versus-host disease (GVHD) or need to use immunosuppressive agents
• Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood HBV DNA titer test is not within the normal reference range; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) Antibody positive; CMV DNA test positive; Syphilis test positive
• Severe heart disease
• Systemic diseases judged by the investigator to be unstable: including but not limited to severe liver, kidney or metabolic diseases that require medication
• Within 7 days before screening, there are active infections or uncontrollable infections that require systemic treatment (except for mild urogenital infections and upper respiratory tract infections)
• Women who are pregnant or breastfeeding, and female subjects who plan to become pregnant within 1 year after cell reinfusion, or male subjects whose partners plan to become pregnant within 1 year after cell reinfusion
• Those who have received CAR-T therapy or other genetically modified cell therapy before screening
• Subjects who are receiving systemic steroid therapy at the time of screening and the investigator determines that they need long-term systemic steroid therapy during the treatment period (except for inhaled or topical use)
• Participated in other clinical studies within 3 months before screening
• Central nervous system metastases are known to occur and for suspected central nervous system metastases, head MRI examination is required to rule out
• Patients with partial or complete intestinal obstruction and complete biliary obstruction that cannot be relieved by active treatment
• With more than a moderate amount of ascites, or after conservative medical treatment (such as diuresis, sodium restriction, excluding ascites drainage) for 2 weeks, the ascites still shows a progressive increase
• According to the researcher's judgment, it does not meet the situation of cell preparation

Sponsors & Collaborators

• PersonGen BioTherapeutics (Suzhou) Co., Ltd.: lead

Study Sites (1)

Bin Hu Hospital

Hefei, Anhui, 230601, China

RECRUITING

Central Study Contacts

yangyi bao

CONTACT

186-5516-8357; 761760565@qq.com

huimin meng

CONTACT

0551-65728070; huimin.meng@persongen.com.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 7, 2020
• First Posted: December 31, 2020
• Study Start: September 1, 2019
• Primary Completion: February 26, 2021
• Study Completion: December 1, 2021
• Last Updated: December 31, 2020

Record last verified: 2020-12

Locations

CN (1)